[{"id":"ff30d699-6a53-417a-9123-6d01ce11b0e9","acronym":"LITESPARK-005","url":"https://clinicaltrials.gov/study/NCT04195750","created_at":"2021-01-18T20:26:57.399Z","updated_at":"2025-02-25T14:07:37.008Z","phase":"Phase 3","brief_title":"A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","source_id_and_acronym":"NCT04195750 - LITESPARK-005","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 755","initiation":"Initiation: 02/27/2020","start_date":" 02/27/2020","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 09/17/2026","study_completion_date":" 09/17/2026","last_update_posted":"2025-02-17"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"67176e4e-5f06-435a-a426-189730ad7d5a","acronym":"LITESPARK-015","url":"https://clinicaltrials.gov/study/NCT04924075","created_at":"2021-07-05T17:36:40.354Z","updated_at":"2025-02-25T15:26:55.556Z","phase":"Phase 2","brief_title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","source_id_and_acronym":"NCT04924075 - LITESPARK-015","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KIT • PDGFRA • VHL • EPAS1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • VHL • EPAS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan)"],"overall_status":"Recruiting","enrollment":" Enrollment 322","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 06/04/2029","primary_completion_date":" 06/04/2029","study_txt":" Completion: 06/04/2029","study_completion_date":" 06/04/2029","last_update_posted":"2025-02-11"},{"id":"be1fb378-e645-4d44-9ccb-5000075d9948","acronym":"LITESPARK-013","url":"https://clinicaltrials.gov/study/NCT04489771","created_at":"2021-01-18T21:34:23.608Z","updated_at":"2025-02-25T15:26:26.915Z","phase":"Phase 2","brief_title":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","source_id_and_acronym":"NCT04489771 - LITESPARK-013","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 09/13/2020","start_date":" 09/13/2020","primary_txt":" Primary completion: 02/10/2023","primary_completion_date":" 02/10/2023","study_txt":" Completion: 10/04/2026","study_completion_date":" 10/04/2026","last_update_posted":"2025-02-11"},{"id":"b28bd860-d85f-4416-a7a1-e5a3d9f0f8a8","acronym":"MK-6482-030","url":"https://clinicaltrials.gov/study/NCT06234605","created_at":"2024-02-01T00:20:48.241Z","updated_at":"2025-02-25T16:11:25.934Z","phase":"Phase 1","brief_title":"A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma","source_id_and_acronym":"NCT06234605 - MK-6482-030","lead_sponsor":"HiberCell, Inc.","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Welireg (belzutifan) • HC-7366"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-11-22"}]